Neuren Pharmaceuticals Limited (ASX: NEU)
Australia
· Delayed Price · Currency is AUD 12.43
-1.26 (-9.20%)
Nov 21, 2024, 4:10 PM AEST
Neuren Pharmaceuticals Balance Sheet
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Cash & Equivalents | 2.57 | 17.09 | 40.18 | 36.78 | 24.19 | 13.84 | Upgrade
|
| Short-Term Investments | 210.6 | 211.45 | - | - | - | - | Upgrade
|
| Cash & Short-Term Investments | 213.17 | 228.54 | 40.18 | 36.78 | 24.19 | 13.84 | Upgrade
|
| Cash Growth | 148.82% | 468.79% | 9.24% | 52.07% | 74.72% | -41.28% | Upgrade
|
| Accounts Receivable | 14.87 | - | - | 0.01 | - | 0.01 | Upgrade
|
| Other Receivables | - | 14.41 | 1.09 | 1.42 | 0.76 | 0.54 | Upgrade
|
| Receivables | 14.87 | 14.41 | 1.09 | 1.42 | 0.76 | 0.55 | Upgrade
|
| Prepaid Expenses | - | 4.21 | 1.98 | 1.84 | - | - | Upgrade
|
| Total Current Assets | 228.04 | 247.16 | 43.25 | 40.04 | 24.94 | 14.4 | Upgrade
|
| Property, Plant & Equipment | 0.04 | 0.04 | 0.02 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Long-Term Deferred Tax Assets | 0.08 | 0.77 | - | - | - | - | Upgrade
|
| Total Assets | 228.15 | 247.97 | 43.27 | 40.06 | 24.95 | 14.41 | Upgrade
|
| Accounts Payable | 4.48 | 0.68 | 0.26 | 0.25 | 0.17 | 0.34 | Upgrade
|
| Accrued Expenses | - | 2.74 | 0.72 | 0.56 | 0.59 | 0.22 | Upgrade
|
| Current Income Taxes Payable | 4.19 | 37.12 | - | - | - | - | Upgrade
|
| Other Current Liabilities | 0.31 | 2.23 | 0.7 | - | - | - | Upgrade
|
| Total Current Liabilities | 8.97 | 42.76 | 1.68 | 0.8 | 0.75 | 0.56 | Upgrade
|
| Total Liabilities | 9 | 42.76 | 1.68 | 0.8 | 0.75 | 0.56 | Upgrade
|
| Common Stock | 175.7 | 173.13 | 167.74 | 167.58 | 145.57 | 126.43 | Upgrade
|
| Retained Earnings | 46.4 | 38.39 | -118.69 | -118.88 | -111.08 | -104.08 | Upgrade
|
| Comprehensive Income & Other | -2.95 | -6.31 | -7.46 | -9.45 | -10.28 | -8.5 | Upgrade
|
| Total Common Equity | 219.15 | 205.21 | 41.59 | 39.25 | 24.2 | 13.85 | Upgrade
|
| Shareholders' Equity | 219.15 | 205.21 | 41.59 | 39.25 | 24.2 | 13.85 | Upgrade
|
| Total Liabilities & Equity | 228.15 | 247.97 | 43.27 | 40.06 | 24.95 | 14.41 | Upgrade
|
| Net Cash (Debt) | 213.17 | 228.54 | 40.18 | 36.78 | 24.19 | 13.84 | Upgrade
|
| Net Cash Growth | 148.82% | 468.79% | 9.24% | 52.07% | 74.72% | -41.28% | Upgrade
|
| Net Cash Per Share | 1.63 | 1.75 | 0.31 | 0.31 | 0.23 | 0.14 | Upgrade
|
| Filing Date Shares Outstanding | 127.82 | 127.27 | 125.97 | 125.97 | 114.61 | 100.17 | Upgrade
|
| Total Common Shares Outstanding | 127.82 | 127.27 | 125.97 | 125.97 | 114.61 | 100.17 | Upgrade
|
| Working Capital | 219.07 | 204.39 | 41.57 | 39.24 | 24.19 | 13.84 | Upgrade
|
| Book Value Per Share | 1.71 | 1.61 | 0.33 | 0.31 | 0.21 | 0.14 | Upgrade
|
| Tangible Book Value | 219.15 | 205.21 | 41.59 | 39.25 | 24.2 | 13.85 | Upgrade
|
| Tangible Book Value Per Share | 1.71 | 1.61 | 0.33 | 0.31 | 0.21 | 0.14 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.